|1.||Hattori, Kazuo: 2 articles (09/2003 - 03/2003)|
|2.||Miwa, Masanori: 2 articles (09/2003 - 03/2003)|
|3.||Eda, Hiroyuki: 2 articles (09/2003 - 03/2003)|
|4.||Ishikawa, Tohru: 2 articles (09/2003 - 03/2003)|
|5.||Ura, Masako: 2 articles (09/2003 - 03/2003)|
|6.||Shimma, Nobuo: 2 articles (09/2003 - 03/2003)|
|7.||Ishitsuka, Hideo: 2 articles (09/2003 - 03/2003)|
|8.||Tanimura, Hiromi: 2 articles (09/2003 - 03/2003)|
|9.||Banken, Ludger: 1 article (04/2004)|
|10.||Bellibas, S Eralp: 1 article (04/2004)|
04/01/2004 - "On the basis of these findings, a 10-to-30-mg dose range of Ro 09-4889 combined with capecitabine could be appropriate for further evaluation in cancer patients."
09/20/2003 - "These results indicate that the antitumor activity of capecitabine is directly affected by DPD activities in tumor tissues and therefore, the combination of capecitabine and a tumor selective DPD inhibitor, RO0094889, will be beneficial to patients who have tumors with high levels of DPD."
09/20/2003 - "Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889."
03/10/2003 - "Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine."
09/20/2003 - "As compared to 5-ethynyluracil or 5-vinyluracil, which inhibited DPD not only in tumor tissues but also in other non-cancerous tissues, the effective dose range of RO0094889 in augmenting the efficacy of capecitabine was much broader. "
|3.||Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)
|5.||Complementary DNA (cDNA)